News

December 6, 2017

Bavencio Fails to Increase Survival of Advanced Gastric Cancer Patients in Phase 3 Trial

News

Bavencio (avelumab) failed to increase overall survival of unresectable, recurrent, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma patients in a Phase 3 trial, Merck KGaA and Pfizer announced. The JAVELIN Gastric ... Read more

December 5, 2017December 5, 2017

Phase 3 Opdivo Trial Ends Early After Showing Better Survival Rates than Docetaxel in NSCLC

News

A Phase 3 study comparing Opdivo (nivolumab) to Taxotere (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC) who didn’t respond to platinum-based chemotherapy was ended early after an independent ... Read more

December 4, 2017December 4, 2017

Cerenis May Develop HDL Cholesterol as Tumor Visualization Tool for Targeted Cancer Therapy

News

Cerenis Therapeutics has recruited its first patients into a trial to test whether HDL particles — more commonly known as good cholesterol — can be used to visualize tumors. If proven ... Read more

December 1, 2017December 1, 2017

EMA to Review Opdivo-Yervoy Combo as Treatment for Renal Cancer

News

The European Medicines Agency (EMA) will review Bristol-Myers Squibb’s application seeking to expand the indications for Opdivo (nivolumab) plus Yervoy (ipilimumab) to include intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). ... Read more

November 30, 2017

IMO-2125, Yervoy Combo is on Fast Track for Treating Refractory Metastatic Melanoma

News

The U.S. Food and Drug Administration (FDA) granted fast track status to Idera Pharmaceuticals‘ IMO-2125, in combination with Yervoy (ipilimumab), for the treatment of metastatic melanoma patients whose disease progressed ... Read more

November 29, 2017November 29, 2017

Tecentriq Add-on Improved Outcomes in Untreated Advanced Lung Cancer Patients

News

Adding Tecentriq (atezolizumab) to a treatment of Avastin (bevacizumab) and chemotherapy significantly prolonged the time to disease progression or death in people with previously untreated advanced non-squamous non-small cell lung ... Read more

November 28, 2017November 28, 2017

Imfinzi Increases Time for Non-small Cell Lung Cancer to Progress, Phase 3 Trial Shows

News

AstraZeneca’s Imfinzi (durvalumab) significantly lengthened the time it took for a patient’s non-small cell lung cancer to progress after chemotherapy and radiation, a Phase 3 clinical trial showed. The trial compared the ... Read more

November 27, 2017November 27, 2017

Seattle Children’s $1B Fundraising Campaign Focuses on Immuno-Oncology Research

News

Seattle Children’s recently launched a $1 billion initiative aimed at transforming children’s health by investing in innovative research and immuno-oncology. Last year, Seattle Children’s received more than 420,000 visitors — ... Read more

November 22, 2017November 22, 2017

Seattle Children’s Launches 2-Pronged CAR T-Cell Therapy Trial in Refractory Acute Lymphoblastic Leukemia

News

Seattle Children’s Hospital has launched a new clinical trial, PLAT-05 (NCT03330691), and is currently recruiting participants to test a new CAR T-cell immunotherapy targeting two proteins expressed on cancer cells of certain ... Read more

November 17, 2017

Combining Opdivo with BMS-986205 Shows Promise in Advanced Cervical, Bladder Cancers

News

Bristol-Myers Squibb announced encouraging results of combining Opdivo (nivolumab) with the investigational IDO1 Inhibitor, BMS-986205, in patients with advanced cancers and heavily treated with other therapies. The data stems from ... Read more